申请人:Xiamen Biotime Biotechnology Co., Ltd.
公开号:EP4006033A1
公开(公告)日:2022-06-01
A compound represented by formula (I) and a pharmaceutical composition thereof. The compound represented by formula (I) may be used as an adenosine receptor inhibitor, especially as an A2A and/or A2B inhibitor, for example, the compound may be used to prevent or treat diseases related to A2A and/or A2B activity or expression.
一种由式(I)代表的化合物及其药物组合物。式(I)代表的化合物可用作腺苷受体抑制剂,尤其是 A2A 和/或 A2B 抑制剂,例如,该化合物可用于预防或治疗与 A2A 和/或 A2B 活性或表达有关的疾病。